Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Other Non-Current Assets: 2024-2025

Historic Other Non-Current Assets for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $13.8 million.

  • Kura Oncology's Other Non-Current Assets rose 67.40% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 67.40%. This contributed to the annual value of $7.8 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Kura Oncology reported Other Non-Current Assets of $13.8 million as of Q3 2025, which was up 30.34% from $10.6 million recorded in Q2 2025.
  • In the past 5 years, Kura Oncology's Other Non-Current Assets registered a high of $13.8 million during Q3 2025, and its lowest value of $7.4 million during Q2 2024.
  • For the 2-year period, Kura Oncology's Other Non-Current Assets averaged around $9.2 million, with its median value being $8.2 million (2024).
  • Data for Kura Oncology's Other Non-Current Assets shows a peak YoY skyrocketed of 67.40% (in 2025) over the last 5 years.
  • Kura Oncology's Other Non-Current Assets (Quarterly) stood at $7.8 million in 2024, then soared by 67.40% to $13.8 million in 2025.
  • Its last three reported values are $13.8 million in Q3 2025, $10.6 million for Q2 2025, and $9.1 million during Q1 2025.